Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Prospective, Open-Label, Randomized Clinical Trial Evaluating the Augmenting of Anti-SARS-CoV2 Immunity in Kidney Transplant Recipients Via a Heterologous Additional Dose With Janssen Ad26.CoV2.S Vaccine

NCT05220397 is registered in ClinicalTrials.gov with Mark Stegall as lead sponsor.

NCT NCT05220397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05220397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Prospective, Open-Label, Randomized Clinical Trial Evaluating the Augmenting of Anti-SARS-CoV2 Immunity in Kidney Transplant Recipients Via a Heterologous Additional Dose With Janssen Ad26.CoV2.S Vaccine
Lead sponsor
Mark Stegall
Phase
Phase 3
Overall status
Terminated
Start date
April 11, 2022
Completion date
February 28, 2025
Enrollment
468 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant recipient